一项评估镰状细胞病参与者服用 Inclacumab 的长期安全性的研究
一项开放标签扩展研究,以评估对已参加 Inclacumab 临床试验的镰状细胞病患者服用 Inclacumab 的长期安全性
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
研究概览
详细说明
The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.
All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Atlántico
-
Barranquilla、Atlántico、哥伦比亚、080020
- Clinica de la Costa Ltda.
-
-
Cesar Department
-
Valledupar、Cesar Department、哥伦比亚、200001
- Sociedad de Oncología y hematología del Cesar
-
-
-
-
-
Adana、土耳其(türkiye)、01130
- Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
-
Adana、土耳其(türkiye)、01250
- Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
-
Ankara、土耳其(türkiye)、06430
- Hacettepe University Ihsan Dogramaci Children Hospital
-
-
-
-
-
Dar es Salaam、坦桑尼亚、11101
- National Institute for Medical Research (NIMR)
-
-
-
-
-
Enugu、尼日利亚、460000
- University of Nigeria Teaching Hospital
-
Kaduna、尼日利亚、800212
- Barau Dikko Teaching Hospital/Kaduna State University
-
Kano、尼日利亚、700223
- Aminu Kano Teaching Hospital
-
Lagos、尼日利亚、100254
- Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
-
-
Cross River State
-
Calabar、Cross River State、尼日利亚、540242
- University of Calabar Teaching Hospital
-
-
Federal Capital Territory
-
Abuja、Federal Capital Territory、尼日利亚、900211
- National Hospital Abuja
-
Gwagwalada、Federal Capital Territory、尼日利亚、902101
- University of Abuja Teaching Hospital
-
-
Kaduna State
-
Zaria、Kaduna State、尼日利亚、810105
- Ahmadu Bello University Teaching Hospital
-
-
-
-
-
Rio de Janeiro、巴西、20211-030
- Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
-
São Paulo、巴西、08270-070
- Casa de Saude Santa Marcelina
-
São Paulo、巴西、01232-010
- Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
-
São Paulo、巴西、08270-120
- CEPEC-Centro de Pesquisa Clinica
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、41253-190
- Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
-
-
Pernambuco
-
Recife、Pernambuco、巴西、50070-460
- Multihemo Servicos Medicos S/A
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90035-903
- Hospital de Clínicas de Porto Alegre
-
-
São Paulo
-
Ribeirão Preto、São Paulo、巴西、14051-140
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São José do Rio Preto、São Paulo、巴西、15090-000
- Fundação Faculdade Regional de Medicina de São José do Rio Preto
-
-
-
-
Southern
-
Jizan、Southern、沙特阿拉伯、82943
- Prince Mohammed bin Nasser Hospital
-
-
-
-
Alabama
-
Mobile、Alabama、美国、36604
- University of South Alabama Children's and Women's Hospital
-
Mobile、Alabama、美国、36604
- Strada Patient Care Center, Pediatric Hematology
-
Mobile、Alabama、美国、36606
- South Alabama Medical Science Foundation
-
-
Arkansas
-
Little Rock、Arkansas、美国、72202
- Arkansas Children's Hospital
-
-
California
-
Orange、California、美国、92868
- UC Irvine Medical Center
-
-
Connecticut
-
Farmington、Connecticut、美国、06030
- UConn-Neag Comprehensive Cancer Center
-
-
Illinois
-
Chicago、Illinois、美国、60612
- University of Illinois Hospital and Health Sciences System (UI Health)
-
Chicago、Illinois、美国、60612
- University of Illinois at Chicago (UIC) Clinical Research Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、美国、02215
- Dana-Farber Cancer Institute IDS Pharmacy
-
Boston、Massachusetts、美国、02115
- Brigham And Woman's Hospital
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan Hospitals - Michigan Medicine
-
-
New York
-
The Bronx、New York、美国、10461
- Jacobi Medical Center
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- Duke University Medical Center
-
Durham、North Carolina、美国、27710
- DUMC Investigational Drug Services Pharmacy
-
-
Texas
-
Houston、Texas、美国、77030
- McGovern Medical School at UTHealth
-
Houston、Texas、美国、77030
- UT Physicians Comprehensive Sickle Cell Center Houston
-
Houston、Texas、美国、77030
- UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
-
-
-
-
-
Eldoret、肯尼亚、30100
- International Cancer Institute
-
Nairobi、肯尼亚、00100
- Gertrude's Children's Hospital
-
Nairobi、肯尼亚、00100
- Kenya Medical Research Institute - Centre for Respiratory Disease Research
-
Nairobi、肯尼亚、00200
- Strathmore University CREATES
-
-
Siaya County
-
Kisumu、Siaya County、肯尼亚、40600
- KEMRI/CRDR Siaya Clinical Research Annex
-
-
-
-
-
Muscat、阿曼、123
- Sultan Qaboos University Hospital
-
-
-
-
Beirut
-
Hamra、Beirut、黎巴嫩
- American University of Beirut Medical Center
-
-
North Lebanon
-
Tripoli、North Lebanon、黎巴嫩
- Nini Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Participants who meet all the following criteria will be eligible for study enrollment:
-
Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.
-
Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.
-
Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.
Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.
-
If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.
-
Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.
Exclusion Criteria:
Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:
- Female participant who is breastfeeding or pregnant.
- Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
- Participant withdrew consent from the originating inclacumab clinical study.
- Participant was lost to follow-up from the originating inclacumab clinical study.
- Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Inclacumab 30 mg/kg
Inclacumab 30 mg/kg administered intravenously (IV) |
Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
大体时间:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs. |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Annualized Rate of Vaso-occlusive Crises (VOCs)
大体时间:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
大体时间:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Number of Inpatient Hospitalization Days for a VOC
大体时间:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of SCD-related Urgent Care Visits
大体时间:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
大体时间:From first dose of study treatment (Day 1) up to Week 48
|
The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure. |
From first dose of study treatment (Day 1) up to Week 48
|
|
Annualized Rate of Complicated VOCs
大体时间:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of Red Blood Cell (RBC) Transfusions
大体时间:From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
合作者和调查者
赞助
调查人员
- 研究主任:Pfizer CT.gov Call Center、Pfizer
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- GBT2104-133
- 2020-005289-32 (EudraCT编号)
- C5361003 (其他标识符:Alias Study Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.